Back to dataset

Inflammatory bowel disease national clinical audit of biological therapies (2016) Data field description file biological therapies audit 2016

You're previewing the first 4 rows of this file.

Download this file
Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Column 7 Column 8 Column 9
Health board / Trust name Sitename Participation status Number of patients entered to the audit between 1 March 2015 and 29 February 2016 Number of patients with adequate pre-treatment screening Number of patients with documented follow-up at 3 months Number of patients with documented disease activity index at 3 months Number of patients being treated with infliximab (Remicade) Number of patients being treated with infliximab biosimilars (Inflectra / Remsima)
Name of Health Board / Trust Name of site Did site participate Number of patients entered to the audit between 1 March 2015 and 29 February 2016 Percentage of patients with adequate pre-treatment screening Percentage of patients with documented follow-up at 3 months Percentage of patients with documented disease activity index at 3 months Percentage of patients being treated with infliximab (Remicade) Percentage of patients being treated with infliximab biosimilars (Inflectra / Remsima)
text text text integer Percentage (integer) Percentage (integer) Percentage (integer) Percentage (integer) Percentage (integer)
text text text 0 0% (0/0) 0% (0/0) 0% (0/0) 0% (0/0) 0% (0/0)